ReviewKidney3602026
Noncoding RNAs as Targets of Acute Kidney Injury Therapy: Ready for Primetime?
Review in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
AKI is a common clinical syndrome characterized by its complex pathophysiology and lack of effective therapeutic options, resulting in significantly increased mortality rates and a higher risk of progression to CKD. In recent years, noncoding RNAs (ncRNAs) have emerged as crucial regulators of gene expression and have been implicated in the onset and progression of AKI, particularly microRNAs, long noncoding RNAs, and circular RNAs. A growing body of research indicates that ncRNAs are not only involved in pathologic processes such as inflammation, apoptosis, and oxidative stress but also serve as promising early diagnostic biomarkers and potential therapeutic targets. This review systematically explores the molecular mechanisms of ncRNAs in AKI, their potential as therapeutic tools, and highlights recent advancements in the field along with the challenges of clinical translation. Ultimately, we assess whether ncRNA-targeted therapies are ready for clinical application in the management of AKI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.